Naiara Perurena

Dr. Naiara Perurena

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJuwon Park
Juwon Park
RWRobert W. Wysocki
Robert W. Wysocki
ZAZohreh Amoozgar
Zohreh Amoozgar
LMLaura Maiorino
Laura Maiorino
MFMiriam R. Fein
Miriam R. Fein
MEMikala Egeblad
Mikala Egeblad
Treatment with DNase I–coated nanoparticles prevents metastasis by targeting neutrophil extracellular traps induced by cancer cells in a mouse model.

21 February 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
AVAdrian Vallejo
Adrian Vallejo
Naiara PerurenaNaiara Perurena
Naiara Perurena
EGElisabet Guruceaga
Elisabet Guruceaga
PMPawel K. Mazur
Pawel K. Mazur
SMSusana Martinez-Canarias
Susana Martinez-Canarias
SVSilvestre Vicent
Silvestre Vicent
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative therapeutic strategies. Here we report the identification of a common transcriptional signature across mutant KRAS cancers of distinct tissue origin that includes the transcription factor FOSL1. High FOSL1 expression identifies mutant KRAS lung and pancreatic cancer patients with the worst survival outcome. Furthermore, FOSL1 genetic inhibition is detrimental to both KRAS-driven tumour types. Mechanistically, FOSL1 links the KRAS oncogene to components of the mitotic machinery, a pathway previously postulated to function orthogonally to oncogenic KRAS. FOSL1 targets include AURKA, whose inhibition impairs viability of mutant KRAS cells. Lastly, combination of AURKA and MEK inhibitors induces a deleterious effect on mutant KRAS cells. Our findings unveil KRAS downstream effectors that provide opportunities to treat KRAS-driven cancers.

1 May 2018 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
DADaniel Ajona
Daniel Ajona
CZCarolina Zandueta
Carolina Zandueta
LCLeticia Corrales
Leticia Corrales
HMHaritz Moreno
Haritz Moreno
MPMaría J. Pajares
María J. Pajares
FLFernando Lecanda
Fernando Lecanda
Rationale: C5aR1 (CD88), a receptor for complement anaphylatoxin C5a, is a potent immune mediator. Its impact on malignant growth and dissemination of non–small cell lung cancer cells is poorly understood. Objectives: To investigate the contribution of the C5a/C5aR1 axis to the malignant phenotype of non–small cell lung cancer cells, particularly in skeletal colonization, a preferential lung metastasis site. Methods: Association between C5aR1 expression and clinical outcome was assessed in silico and validated by immunohistochemistry. Functional significance was evaluated by lentiviral gene silencing and ligand l-aptamer inhibition in in vivo models of lung cancer bone metastasis. In vitro functional assays for signaling, migration, invasion, metalloprotease activity, and osteoclastogenesis were also performed. Measurements and Main Results: High levels of C5aR1 in human lung tumors were significantly associated with shorter recurrence-free survival, overall survival, and bone metastasis. Silencing of C5aR1 in lung cancer cells led to a substantial reduction in skeletal metastatic burden and osteolysis in in vivo models. Furthermore, metalloproteolytic, migratory, and invasive tumor cell activities were modulated in vitro by C5aR1 stimulation or gene silencing. l-Aptamer blockade or C5aR1 silencing significantly reduced the osseous metastatic activity of lung cancer cells in vivo. This effect was associated with decreased osteoclastogenic activity in vitro and was rescued by the exogenous addition of the chemokine CXCL16. Conclusions: Disruption of C5aR1 signaling in lung cancer cells abrogates their tumor-associated osteoclastogenic activity, impairing osseous colonization. This study unveils the role played by the C5a/C5aR1 axis in lung cancer dissemination and supports its potential use as a novel therapeutic target.

16 April 2024 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
Naiara PerurenaNaiara Perurena
Naiara Perurena
LSLisa Situ
Lisa Situ
KCKaren Cichowski
Karen Cichowski

9 October 2024 in Nature
Verified
Journal Article
Open access
PDF file
ASAmy E. Schade
Amy E. Schade
Naiara PerurenaNaiara Perurena
Naiara Perurena
YYYoona Yang
Yoona Yang
CRCarrie L. Rodriguez
Carrie L. Rodriguez
AKAnjana Krishnan
Anjana Krishnan
KCKaren Cichowski
Karen Cichowski
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6. However, in contrast to hormone-receptor-positive tumours, it is still unclear whether or how triple-negative disease will respond to PI3K pathway inhibitors7. Here we describe a promising AKT-inhibitor-based therapeutic combination for TNBC. Specifically, we show that AKT inhibitors synergize with agents that suppress the histone methyltransferase EZH2 and promote robust tumour regression in multiple TNBC models in vivo. AKT and EZH2 inhibitors exert these effects by first cooperatively driving basal-like TNBC cells into a more differentiated, luminal-like state, which cannot be effectively induced by either agent alone. Once TNBCs are differentiated, these agents kill them by hijacking signals that normally drive mammary gland involution. Using a machine learning approach, we developed a classifier that can be used to predict sensitivity. Together, these findings identify a promising therapeutic strategy for this highly aggressive tumour type and illustrate how deregulated epigenetic enzymes can insulate tumours from oncogenic vulnerabilities. These studies also reveal how developmental tissue-specific cell death pathways may be co-opted for therapeutic benefit.

21 February 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
BCBorja Ruiz-Fernández de Córdoba
Borja Ruiz-Fernández de Córdoba
HMHaritz Moreno
Haritz Moreno
KVKarmele Valencia
Karmele Valencia
Naiara PerurenaNaiara Perurena
Naiara Perurena
PRPablo Ruedas
Pablo Ruedas
RMRafael Martínez-Monge
Rafael Martínez-Monge
Locoregional failure (LRF) in patients with breast cancer post-surgery and post-irradiation is linked to a dismal prognosis. In a refined new model, we identified ectonucleotide pyrophosphatase/phosphodiesterase 1/CD203a (ENPP1) to be closely associated with LRF. ENPP1hi circulating tumor cells (CTC) contribute to relapse by a self-seeding mechanism. This process requires the infiltration of polymorphonuclear myeloid-derived suppressor cells and neutrophil extracellular trap (NET) formation. Genetic and pharmacologic ENPP1 inhibition or NET blockade extends relapse-free survival. Furthermore, in combination with fractionated irradiation, ENPP1 abrogation obliterates LRF. Mechanistically, ENPP1-generated adenosinergic metabolites enhance haptoglobin (HP) expression. This inflammatory mediator elicits myeloid invasiveness and promotes NET formation. Accordingly, a significant increase in ENPP1 and NET formation is detected in relapsed human breast cancer tumors. Moreover, high ENPP1 or HP levels are associated with poor prognosis. These findings unveil the ENPP1/HP axis as an unanticipated mechanism exploited by tumor cells linking inflammation to immune remodeling favoring local relapse. Significance: CTC exploit the ENPP1/HP axis to promote local recurrence post-surgery and post-irradiation by subduing myeloid suppressor cells in breast tumors. Blocking this axis impairs tumor engraftment, impedes immunosuppression, and obliterates NET formation, unveiling new opportunities for therapeutic intervention to eradicate local relapse and ameliorate patient survival. This article is highlighted in the In This Issue feature, p. 1171